VaxGen sells anthrax vaccine to its old rival

Reduced to a skeleton crew and a bleak outlook, South San Francisco-based VaxGen sold its experimental anthrax vaccine to its former chief rival, Emergent BioSolutions, for $2 million down and up to $8 million in milestones.

VaxGen began to founder in 2006 when the government revoked an $877 million contract for the VaxGen vaccine after the company failed to start a human trial on schedule. Now Emergent, which makes the only FDA-approved anthrax vaccine now available, says it plans to advance the experimental vaccine.

VaxGen, which once had more than 200 employees, has been reduced to a staff of about six after a planned merger with Raven biotechnologies fell through.

- here's VaxGen's release on the deal

Related Articles:
Struggling VaxGen sells anthrax vaccine to rival
VaxGen faces possible liquidation after merger flops
Shareholders stymie VaxGen, Raven merger
Momentum builds for VaxGen, Raven merger
VaxGen slashes staff--again

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.